122 related articles for article (PubMed ID: 11596035)
1. A lipophilic vasoactive intestinal peptide analog enhances the antiproliferative effect of chemotherapeutic agents on cancer cell lines.
Gelber E; Granoth R; Fridkin M; Dreznik Z; Brenneman DE; Moody TW; Gozes I
Cancer; 2001 Oct; 92(8):2172-80. PubMed ID: 11596035
[TBL] [Abstract][Full Text] [Related]
2. VIP receptor antagonists and chemotherapeutic drugs inhibit the growth of breast cancer cells.
Moody TW; Leyton J; Chan D; Brenneman DC; Fridkin M; Gelber E; Levy A; Gozes I
Breast Cancer Res Treat; 2001 Jul; 68(1):55-64. PubMed ID: 11678309
[TBL] [Abstract][Full Text] [Related]
3. A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth.
Moody TW; Zia F; Draoui M; Brenneman DE; Fridkin M; Davidson A; Gozes I
Proc Natl Acad Sci U S A; 1993 May; 90(10):4345-9. PubMed ID: 8389448
[TBL] [Abstract][Full Text] [Related]
4. A vasoactive intestinal peptide antagonist inhibits the growth of glioblastoma cells.
Sharma A; Walters J; Gozes Y; Fridkin M; Brenneman D; Gozes I; Moody TW
J Mol Neurosci; 2001 Dec; 17(3):331-9. PubMed ID: 11859929
[TBL] [Abstract][Full Text] [Related]
5. A vasoactive intestinal peptide receptor analog alters the expression of homeobox genes.
Steingart RA; Heldenberg E; Pinhasov A; Brenneman DE; Fridkin M; Gozes I
Life Sci; 2002 Oct; 71(21):2543-52. PubMed ID: 12270759
[TBL] [Abstract][Full Text] [Related]
6. Vasoactive intestinal peptide (VIP) inhibits human renal cell carcinoma proliferation.
Vacas E; Fernández-Martínez AB; Bajo AM; Sánchez-Chapado M; Schally AV; Prieto JC; Carmena MJ
Biochim Biophys Acta; 2012 Oct; 1823(10):1676-85. PubMed ID: 22728770
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo treatment of colon cancer by VIP antagonists.
Levy A; Gal R; Granoth R; Dreznik Z; Fridkin M; Gozes I
Regul Pept; 2002 Nov; 109(1-3):127-33. PubMed ID: 12409224
[TBL] [Abstract][Full Text] [Related]
8. Expression of vasoactive intestinal peptide and functional VIP receptors in human prostate cancer: antagonistic action of a growth-hormone-releasing hormone analog.
Collado B; Carmena MJ; Sánchez-Chapado M; Ruíz-Villaespesa A; Bajo AM; Fernández-Martínez AB; Varga JL; Schally AV; Prieto JC
Int J Oncol; 2005 Jun; 26(6):1629-35. PubMed ID: 15870879
[TBL] [Abstract][Full Text] [Related]
9. A lymphocyte-generated fragment of vasoactive intestinal peptide with VPAC1 agonist activity and VPAC2 antagonist effects.
Summers MA; O'Dorisio MS; Cox MO; Lara-Marquez M; Goetzl EJ
J Pharmacol Exp Ther; 2003 Aug; 306(2):638-45. PubMed ID: 12750439
[TBL] [Abstract][Full Text] [Related]
10. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide stimulate interleukin-6 production in prostate cancer cells and prostatic epithelial cells.
Nagakawa O; Junicho A; Akashi T; Koizumi K; Matsuda T; Fuse H; Saiki I
Oncol Rep; 2005 Jun; 13(6):1217-21. PubMed ID: 15870945
[TBL] [Abstract][Full Text] [Related]
11. (N-stearyl, norleucine17)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist.
Moody TW; Jensen RT; Fridkin M; Gozes I
J Mol Neurosci; 2002; 18(1-2):29-35. PubMed ID: 11931347
[TBL] [Abstract][Full Text] [Related]
12. Effects of the vasoactive intestinal peptide (VIP) and related peptides on glioblastoma cell growth in vitro.
Dufes C; Alleaume C; Montoni A; Olivier JC; Muller JM
J Mol Neurosci; 2003; 21(2):91-102. PubMed ID: 14593209
[TBL] [Abstract][Full Text] [Related]
13. Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines in vitro and in vivo and produces synergistic growth inhibition in combination with other antitumor agents.
Chan DC; Gera L; Stewart JM; Helfrich B; Zhao TL; Feng WY; Chan KK; Covey JM; Bunn PA
Clin Cancer Res; 2002 May; 8(5):1280-7. PubMed ID: 12006549
[TBL] [Abstract][Full Text] [Related]
14. Human H9 cells proliferation is differently controlled by vasoactive intestinal peptide or peptide histidine methionine: implication of a GTP-insensitive form of VPAC1 receptor.
Goursaud S; Pineau N; Becq-Giraudon L; Gressens P; Muller JM; Janet T
J Neuroimmunol; 2005 Jan; 158(1-2):94-105. PubMed ID: 15589042
[TBL] [Abstract][Full Text] [Related]
15. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.
Akesson L; Ahrén B; Edgren G; Degerman E
Endocrinology; 2005 Feb; 146(2):744-50. PubMed ID: 15514088
[TBL] [Abstract][Full Text] [Related]
16. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit T cell-mediated cytotoxicity by inhibiting Fas ligand expression.
Delgado M; Ganea D
J Immunol; 2000 Jul; 165(1):114-23. PubMed ID: 10861043
[TBL] [Abstract][Full Text] [Related]
17. (N-stearyl, norleucine17) VIP hybrid inhibits the growth of pancreatic cancer cell lines.
Zia H; Leyton J; Casibang M; Hau V; Brenneman D; Fridkin M; Gozes I; Moody TW
Life Sci; 2000; 66(5):379-87. PubMed ID: 10670826
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of human neuroblastoma growth by a specific VIP antagonist.
Lilling G; Wollman Y; Goldstein MN; Rubinraut S; Fridkin M; Brenneman DE; Gozes I
J Mol Neurosci; 1994-1995; 5(4):231-9. PubMed ID: 7577366
[TBL] [Abstract][Full Text] [Related]
19. Transglutaminase-mediated polyamination of vasoactive intestinal peptide (VIP) Gln16 residue modulates VIP/PACAP receptor activity.
De Maria S; Metafora S; Metafora V; Morelli F; Robberecht P; Waelbroeck M; Stiuso P; De Rosa A; Cozzolino A; Esposito C; Facchiano A; Cartenì M
Eur J Biochem; 2002 Jul; 269(13):3211-9. PubMed ID: 12084061
[TBL] [Abstract][Full Text] [Related]
20. VIP/PACAP oppositely affects immature and mature dendritic cell expression of CD80/CD86 and the stimulatory activity for CD4(+) T cells.
Delgado M; Reduta A; Sharma V; Ganea D
J Leukoc Biol; 2004 Jun; 75(6):1122-30. PubMed ID: 15020654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
